| Not Yet Recruiting | Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma NCT07303283 | Kai Hu | Phase 2 |
| Not Yet Recruiting | A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy NCT07466901 | Jin LI | N/A |
| Recruiting | An Antibody-armored Dendritic Cell in Patients With Solid Tumors NCT07479667 | Shanghai Cell Therapy Group Co.,Ltd | Phase 1 |
| Not Yet Recruiting | Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma NCT07379489 | Tongji Hospital | — |
| Recruiting | Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: NCT07180693 | European Institute of Oncology | — |
| Not Yet Recruiting | Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients NCT07101159 | Fujian Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junct NCT07092449 | Tang-Du Hospital | N/A |
| Recruiting | CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cance NCT07019363 | Fudan University | Phase 3 |
| Not Yet Recruiting | Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer NCT07005557 | Fudan University | Phase 3 |
| Recruiting | Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma NCT06950814 | West China Hospital | — |
| Recruiting | Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study NCT06719206 | Mälardalen University | N/A |
| Active Not Recruiting | MRD in PAAD Adjuvant Therapy NCT06867146 | Peking Union Medical College Hospital | N/A |
| Recruiting | Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adj NCT06621459 | University Hospital, Brest | — |
| Recruiting | Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma NCT06581315 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Active Not Recruiting | The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer NCT06873178 | China-Japan Friendship Hospital | — |
| Recruiting | Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer NCT06361316 | Kuirong Jiang | N/A |
| Recruiting | Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer NCT06344156 | Sichuan University | Phase 1 |
| Recruiting | Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma NCT06056336 | Guo Xufeng | Phase 2 |
| Recruiting | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations NCT06041776 | Betta Pharmaceuticals Co., Ltd. | Phase 3 |
| Unknown | PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery NCT05468138 | Fudan University | Phase 2 |
| Completed | A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Ner NCT05599334 | Pierre Fabre Medicament | — |
| Unknown | Prognosis of Low-grade Endometrial Stromal Sarcoma NCT05310318 | Lei Li | — |
| Unknown | Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer NCT05189067 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 / Phase 3 |
| Unknown | TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection NCT05111366 | Xianhai Mao | Phase 2 |
| Not Yet Recruiting | A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Po NCT05186506 | Sichuan University | Phase 2 |
| Unknown | A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of NCT04981665 | Zhejiang University | Phase 2 |
| Terminated | Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer NCT05161572 | Fudan University | Phase 2 |
| Recruiting | Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as NCT05292742 | Fujian Medical University Union Hospital | Phase 2 |
| Unknown | Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations NCT04969029 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Unknown | Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Rese NCT04682210 | Sun Yat-sen University | Phase 3 |
| Unknown | NAC Followed by RH for the Treatment of LACC NCT03963882 | Lei Li | Phase 2 |
| Active Not Recruiting | Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in NCT06461936 | Chen Xiaoping | — |
| Unknown | Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After R NCT03958435 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Active Not Recruiting | A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients NCT02301286 | Leiden University | Phase 3 |
| Completed | Nordic Adjuvant IFN Melanoma Trial NCT01259934 | Karolinska Institutet | Phase 3 |